Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019

Date : 05/13/2019 @ 1:01PM
Source : PR Newswire (US)
Stock : Halozyme Therapeutics Incorporated (HALO)
Quote : 15.255  -0.545 (-3.45%) @ 4:59AM
After Hours
Last Trade
Last $ 15.26 ▲ 0.00 (0.03%)

Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019

Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Halozyme Therapeutics Charts.

SAN DIEGO, May 13, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will participate in the Bank of America Merrill Lynch Health Care Conference 2019 in Las Vegas, NV. Laurie Stelzer, senior vice president and chief financial officer, will provide an overview of the company on Thursday, May 16 at 12:20 p.m. ET / 9:20 a.m. PT.

A live webcast of the presentation can be accessed through the "Investors" section of www.halozyme.com, and a recording will be made available for 90 days following each event. To access a live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for the treatment of several cancers and has the potential to be used in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical and biotechnology companies, including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx, for its ENHANZE® drug delivery technology. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-2019-300847867.html

SOURCE Halozyme Therapeutics, Inc.

Copyright 2019 PR Newswire

Latest HALO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.